Clinical trial
Phase II Study of Combined Modality Treatment in Primary Testicular…
NCT00210379 · International Extranodal Lymphoma Study Group (IELSG), Other · Completed
Key facts
| NCT number | NCT00210379 |
|---|---|
| Title | Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma |
| Official title | A Phase II Study of CHOP + Rituximab, With Intrathecal Methotrexate Followed by Radiotherapy in Patients With Primary Testicular Non-Hodgkin's Lymphoma |
| Lead sponsor | International Extranodal Lymphoma Study Group (IELSG), Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, B Cell |
| Intervention type | Drug, Procedure |
| Interventions | rituximab, CHOP, intrathecal methotrexate, radiotherapy |
| Enrollment | 64 |
| Start date | Nov 1, 2000 |
| Primary completion | Nov 1, 2004 |
| Completion | Mar 1, 2007 |
| First posted | Sep 21, 2005 |
| Last update posted | Jul 22, 2009 |
| Countries | Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: